Superior Osteogenic Capacity for Bone Tissue Engineering of Fetal Compared with Perinatal and Adult Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) from human adult bone marrow (haMSCs) represent a promising source for bone tissue engineering. However, their low frequencies and limited proliferation restrict their clinical utility. Alternative postnatal, perinatal, and fetal sources of MSCs appear to have different osteogenic capacities, but have not been systematically compared with haMSCs. We investigated the proliferative and osteogenic potential of MSCs from human fetal bone marrow (hfMSCs), human umbilical cord (hUCMSCs), and human adult adipose tissue (hATMSCs), and haMSCs, both in monolayer cultures and after loading into three‐dimensional polycaprolactone‐tricalcium‐phosphate scaffolds.Although all MSCs had comparable immunophenotypes, only hfMSCs and hUCMSCs were positive for the embryonic pluripotency markers Oct‐4 and Nanog. hfMSCs expressed the lowest HLA‐I level (55% versus 95%–99%) and the highest Stro‐1 level (51% versus 10%–27%), and had the greatest colony‐forming unit–fibroblast capacity (1.6×–2.0×; p < .01) and fastest doubling time (32 versus 54–111 hours; p < .01). hfMSCs had the greatest osteogenic capacity, as assessed by von‐Kossa staining, alkaline phosphatase activity (5.1×–12.4×; p < .01), calcium deposition (1.6×–2.7× in monolayer and 1.6×–5.0× in scaffold culture; p < .01), calcium visualized on micro‐computed tomography (3.9×17.6×; p < .01) and scanning electron microscopy, and osteogenic gene induction. Two months after implantation of cellular scaffolds in immunodeficient mice, hfMSCs resulted in the most robust mineralization (1.8×–13.3×; p < .01).The ontological and anatomical origins of MSCs have profound influences on the proliferative and osteogenic capacity of MSCs. hfMSCs had the most proliferative and osteogenic capacity of the MSC sources, as well as being the least immunogenic, suggesting they are superior candidates for bone tissue engineering. STEM CELLS 2009;27:126–137

[1]  N. Scarborough,et al.  Allograft bone. The influence of processing on safety and performance. , 1999, The Orthopedic clinics of North America.

[2]  S. Mowla,et al.  Characterization and genetic manipulation of human umbilical cord vein mesenchymal stem cells: potential application in cell-based gene therapy. , 2008, Rejuvenation research.

[3]  H. Lorenz,et al.  Multilineage cells from human adipose tissue: implications for cell-based therapies. , 2001, Tissue engineering.

[4]  X. Chen,et al.  The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells , 2006, Nature Genetics.

[5]  P. Simmons,et al.  Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. , 1991, Blood.

[6]  M. Zago,et al.  Comparison of Gene Expression of Umbilical Cord Vein and Bone Marrow–Derived Mesenchymal Stem Cells , 2004, Stem cells.

[7]  O. Lee,et al.  Isolation of multipotent mesenchymal stem cells from umbilical cord blood. , 2004, Blood.

[8]  J. Polak,et al.  Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice. , 2008, Blood.

[9]  Huilin Qi,et al.  Identification of genes responsible for osteoblast differentiation from human mesodermal progenitor cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Keelin O'Donoghue,et al.  Human Fetal Mesenchymal Stem Cells as Vehicles for Gene Delivery , 2005, Stem cells.

[11]  J. Glowacki,et al.  Age‐related decline in the osteogenic potential of human bone marrow cells cultured in three‐dimensional collagen sponges , 2001, Journal of cellular biochemistry.

[12]  M. Jansson,et al.  Fetal Mesenchymal Stem-Cell Engraftment in Bone after In Utero Transplantation in a Patient with Severe Osteogenesis Imperfecta , 2005, Transplantation.

[13]  D J Prockop,et al.  Donor variation in the growth properties and osteogenic potential of human marrow stromal cells , 1999, Journal of cellular biochemistry.

[14]  Kenneth M. Yamada,et al.  Taking Cell-Matrix Adhesions to the Third Dimension , 2001, Science.

[15]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[16]  D W Hutmacher,et al.  The effect of rhBMP-2 on canine osteoblasts seeded onto 3D bioactive polycaprolactone scaffolds. , 2004, Biomaterials.

[17]  Christopher H Contag,et al.  Adipose-derived adult stromal cells heal critical-size mouse calvarial defects , 2004, Nature Biotechnology.

[18]  Dolores Baksh,et al.  Human Umbilical Cord Perivascular (HUCPV) Cells: A Source of Mesenchymal Progenitors , 2005, Stem cells.

[19]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[20]  L. Muul,et al.  Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  B. Lim,et al.  Identification of Common Pathways Mediating Differentiation of Bone Marrow‐ and Adipose Tissue‐Derived Human Mesenchymal Stem Cells into Three Mesenchymal Lineages , 2007, Stem cells.

[22]  S. Both,et al.  Bone tissue-engineered implants using human bone marrow stromal cells: effect of culture conditions and donor age. , 2002, Tissue engineering.

[23]  G. Im,et al.  Do adipose tissue-derived mesenchymal stem cells have the same osteogenic and chondrogenic potential as bone marrow-derived cells? , 2005, Osteoarthritis and cartilage.

[24]  A. Bongso,et al.  Comprar Stem Cells. From Bench To Bedside | A. Bongso | 9789814289382 | World Scientific Publishing , 2010 .

[25]  R. Pochampally,et al.  Serum deprivation of human marrow stromal cells (hMSCs) selects for a subpopulation of early progenitor cells with enhanced expression of OCT-4 and other embryonic genes. , 2004, Blood.

[26]  Anthony Atala,et al.  Isolation of amniotic stem cell lines with potential for therapy , 2007, Nature Biotechnology.

[27]  K. Le Blanc,et al.  Mesenchymal stem cells: progress toward promise. , 2005, Cytotherapy.

[28]  A. Abbott.  Cell culture: Biology's new dimension , 2003, Nature.

[29]  A. Meunier,et al.  Tissue-engineered bone regeneration , 2000, Nature Biotechnology.

[30]  O. Ringdén,et al.  Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells , 2003, Bone Marrow Transplantation.

[31]  S. Gerson,et al.  Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH) , 2002, Bone Marrow Transplantation.

[32]  P. Giannoudis,et al.  Mesenchymal stem cell tissue engineering: techniques for isolation, expansion and application. , 2007, Injury.

[33]  A. Caplan.  Adult mesenchymal stem cells for tissue engineering versus regenerative medicine , 2007, Journal of cellular physiology.

[34]  N. Fisk,et al.  Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. , 2001, Blood.

[35]  D. Kaplan,et al.  Role of adult mesenchymal stem cells in bone tissue engineering applications: current status and future prospects. , 2005, Tissue engineering.

[36]  J. Polak,et al.  Comparative osteogenic transcription profiling of various fetal and adult mesenchymal stem cell sources. , 2008, Differentiation; research in biological diversity.

[37]  C. Carlo-Stella,et al.  Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. , 2002, Blood.

[38]  H. Klüter,et al.  Critical Parameters for the Isolation of Mesenchymal Stem Cells from Umbilical Cord Blood , 2004, Stem cells.

[39]  G. Vunjak‐Novakovic,et al.  Silk based biomaterials to heal critical sized femur defects. , 2006, Bone.

[40]  O. Lee,et al.  blood Isolation of multipotent mesenchymal stem cells from umbilical cord , 2010 .

[41]  C. Porada,et al.  Adult mesenchymal stem cells: a pluripotent population with multiple applications. , 2006, Current stem cell research & therapy.

[42]  S. Gronthos,et al.  The STRO-1+ fraction of adult human bone marrow contains the osteogenic precursors. , 1994, Blood.

[43]  A. Bongso,et al.  Stem cells : from bench to bedside , 2005 .

[44]  O. Ringdén,et al.  Immunologic properties of human fetal mesenchymal stem cells. , 2004, American journal of obstetrics and gynecology.

[45]  Robert E Guldberg,et al.  Combination of platelet-rich plasma with polycaprolactone-tricalcium phosphate scaffolds for segmental bone defect repair. , 2007, Journal of biomedical materials research. Part A.

[46]  J. Gimble,et al.  Surface protein characterization of human adipose tissue‐derived stromal cells , 2001, Journal of cellular physiology.

[47]  T. Huser,et al.  Growth, differentiation, and biochemical signatures of rhesus monkey mesenchymal stem cells. , 2008, Stem cells and development.

[48]  Elizabeth Simpson,et al.  Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. , 2003, Blood.

[49]  P. Simmons,et al.  Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1 , 1991 .

[50]  M. Sefton,et al.  Tissue engineering. , 1998, Journal of cutaneous medicine and surgery.

[51]  C. Götherström.  Immunomodulation by Multipotent Mesenchymal Stromal Cells , 2007, Transplantation.

[52]  R. Legeros,et al.  Properties of osteoconductive biomaterials: calcium phosphates. , 2002, Clinical orthopaedics and related research.

[53]  I Zein,et al.  Mechanical properties and cell cultural response of polycaprolactone scaffolds designed and fabricated via fused deposition modeling. , 2001, Journal of biomedical materials research.

[54]  Feng Zhao,et al.  Effects of hypoxia on human mesenchymal stem cell expansion and plasticity in 3D constructs , 2006, Journal of cellular physiology.

[55]  R. Tuan,et al.  Comparison of Proliferative and Multilineage Differentiation Potential of Human Mesenchymal Stem Cells Derived from Umbilical Cord and Bone Marrow , 2007, Stem cells.

[56]  J. Vacanti,et al.  Tissue engineering : Frontiers in biotechnology , 1993 .

[57]  D W Hutmacher,et al.  Novel PCL-based honeycomb scaffolds as drug delivery systems for rhBMP-2. , 2005, Biomaterials.

[58]  A. Barbero,et al.  Real‐time quantitative RT‐PCR analysis of human bone marrow stromal cells during osteogenic differentiation in vitro , 2002, Journal of cellular biochemistry.

[59]  E. Guinan,et al.  Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation , 2003, Transplantation.

[60]  D. Watt,et al.  Galectin‐1 Induces Skeletal Muscle Differentiation in Human Fetal Mesenchymal Stem Cells and Increases Muscle Regeneration , 2006, Stem cells.

[61]  S. Bruder,et al.  Growth kinetics, self‐renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation , 1997, Journal of cellular biochemistry.

[62]  J. Chan,et al.  Widespread Distribution and Muscle Differentiation of Human Fetal Mesenchymal Stem Cells After Intrauterine Transplantation in Dystrophic mdx Mouse , 2007, Stem cells.

[63]  Rui L Reis,et al.  Bone tissue engineering: state of the art and future trends. , 2004, Macromolecular bioscience.

[64]  S. Gronthos,et al.  P78. The stro-1 + cell fraction of adult human bone marrow contains the osteogenic precursors , 1994 .

[65]  J. Chan,et al.  Human First‐Trimester Fetal MSC Express Pluripotency Markers and Grow Faster and Have Longer Telomeres Than Adult MSC , 2007, Stem cells.

[66]  F. Claas,et al.  Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. , 2003, Blood.

[67]  P. Schiller,et al.  Age‐Related Osteogenic Potential of Mesenchymal Stromal Stem Cells from Human Vertebral Bone Marrow , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[68]  P. Kasten,et al.  Mesenchymal stem cell-based HLA-independent cell therapy for tissue engineering of bone and cartilage. , 2006, Current stem cell research & therapy.